Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

Paraiso, K H T; Fedorenko, I V; Cantini, L P; Munko, A C; Hall, M; Sondak, V K; Messina, J L; Flaherty, K T; Smalley, K S M

Paraiso, K H T; Fedorenko, I V; Cantini, L P; Munko, A C; Hall, M; Sondak, V K; Messina, J L; Flaherty, K T; Smalley, K S M.

Affiliation

Paraiso KH; Department of Molecular Oncology, The Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.

Br J Cancer ; 102(12): 1724-30, 2010 Jun 08.

Article in En | MEDLINE | ID: mdl-20531415

Subject(s)

Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases/metabolism; Melanoma/drug therapy; Proto-Oncogene Proteins B-raf/antagonists & inhibitors; Apoptosis/drug effects; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Indoles/pharmacology; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases/metabolism; Mutation; Signal Transduction/drug effects; Sulfonamides/pharmacology; Time Factors

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Resistance, Neoplasm / Proto-Oncogene Proteins B-raf / Extracellular Signal-Regulated MAP Kinases / Melanoma Limits: Humans Language: En Journal: Br J Cancer Year: 2010 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google